Mitogen-Activated Protein Kinase and Exploratory Nuclear Receptor Crosstalk in Cancer Immunotherapy
Overview
Chemistry
Molecular Biology
Authors
Affiliations
The three major mitogen-activated protein kinase (MAPK) pathways (ERK1/2, p38, and JNK/SAPK) are upstream regulators of the nuclear receptor superfamily (NRSF). These ligand-activated transcription factors are divided into subclasses comprising receptors for endocrine hormones, metabolic compounds (e.g., vitamins, diet), xenobiotics, and mediators released from host immune reactions such as tissue injury and inflammation. These internal and external cues place the NRSF at the frontline as sensors and translators of information from the environment towards the genome. For most of the former "orphan" receptors, physiological and synthetic ligands have been identified, opening intriguing opportunities for combination therapies with existing cancer medications. Hitherto, only preclinical data are available, warranting further validation in clinical trials in patients. The current review summarized the existing literature covering the expression and function of NRSF subclasses in human solid tumors and hematopoietic malignancies and their modulatory effects on innate (e.g., macrophages, dendritic cells) and adaptive (i.e., T cell subsets) immune cells, encouraging mechanistic and pharmacological studies in combination with current clinically approved therapeutics against immune checkpoint molecules (e.g., PD1).
Ding B, Li J, Yan J, Jiang C, Qian L, Pan J Front Immunol. 2025; 16:1515605.
PMID: 39963142 PMC: 11830804. DOI: 10.3389/fimmu.2025.1515605.
Special Issue: MAPK Signaling Cascades in Human Health and Diseases.
Seger R Int J Mol Sci. 2024; 25(20).
PMID: 39457006 PMC: 11509016. DOI: 10.3390/ijms252011226.
Zhang Y, Wei J, Kong L, Song M, Zhang Y, Xiao X Sci Rep. 2023; 13(1):22315.
PMID: 38102307 PMC: 10724296. DOI: 10.1038/s41598-023-49597-x.